Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
Article
PubMed
Google Scholar
Li F, Teng H, Liu M, Liu B, Zhang D, Xu Z, Wang Y, Zhou H. Prognostic value of immune-related genes in the tumor microenvironment of bladder cancer. Front Oncol. 2020;10:1302.
Article
PubMed
PubMed Central
Google Scholar
Chen S, Jiang L, Zheng X, Shao J, Wang T, Zhang E, Gao F, Wang X, Zheng J. Clinical use of machine learning-based pathomics signature for diagnosis and survival prediction of bladder cancer. Cancer Sci. 2021;112(7):2905–14.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, et al. NCCN Guidelines Insights: bladder cancer Version 5.2018. J Natl Compr Canc Netw. 2018;16(9):1041–53.
Article
PubMed
Google Scholar
Schneider AK, Chevalier MF, Derre L. The multifaceted immune regulation of bladder cancer. Nat Rev Urol. 2019;16(10):613–30.
Article
CAS
PubMed
Google Scholar
Chen X, Jin Y, Gong L, He D, Cheng Y, Xiao M, Zhu Y, Wang Z, Cao K. Bioinformatics analysis finds immune gene markers related to the prognosis of bladder cancer. Front Genet. 2020;11:607.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jordan B, Meeks JJ. T1 bladder cancer: current considerations for diagnosis and management. Nat Rev Urol. 2019;16(1):23–34.
Article
PubMed
Google Scholar
Na L, Bai Y, Sun Y, Wang Z, Wang W, Yuan L, Zhao C. Identification of 9-Core immune-related genes in bladder urothelial carcinoma prognosis. Front Oncol. 2020;10:1142.
Article
PubMed
PubMed Central
Google Scholar
Chen S, Jiang L, Zhang E, Hu S, Wang T, Gao F, Zhang N, Wang X, Zheng J. A novel nomogram based on machine learning-pathomics signature and neutrophil to lymphocyte ratio for survival prediction of bladder cancer patients. Front Oncol. 2021;11: 703033.
Article
PubMed
PubMed Central
Google Scholar
Wang Y, Chen L, Yu M, Fang Y, Qian K, Wang G, Ju L, Xiao Y, Wang X. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer. Cancer Med. 2020;9(20):7729–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sanmamed MF, Chen L. A Paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2019;176(3):677.
Article
CAS
PubMed
Google Scholar
Liu Y, Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med. 2016;94(5):509–22.
Article
PubMed
CAS
Google Scholar
Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. Curr Opin Oncol. 2015;27(3):191–200.
Article
CAS
PubMed
PubMed Central
Google Scholar
Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Gevaert T. PD-L1 assessment in urothelial carcinoma: a practical approach. Ann Transl Med. 2019;7(22):690.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lobo N, Mount C, Omar K, Nair R, Thurairaja R, Khan MS. Landmarks in the treatment of muscle-invasive bladder cancer. Nat Rev Urol. 2017;14(9):565–74.
Article
CAS
PubMed
Google Scholar
Tan WP, Tan WS, Inman BA. PD-L1/PD-1 Biomarker for metastatic urothelial cancer that progress post-platinum therapy: a systematic review and meta-analysis. Bladder cancer. 2019;5(3):211–23.
Article
PubMed
PubMed Central
Google Scholar
Boegemann M, Aydin AM, Bagrodia A, Krabbe LM. Prospects and progress of immunotherapy for bladder cancer. Expert Opin Biol Ther. 2017;17(11):1417–31.
CAS
PubMed
Google Scholar
Hwang I, Park I, Yoon SK, Lee JL. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors. Clin Genitourin Cancer. 2020;18(2):e122–e133.
Tay C, Qian Y, Sakaguchi S. Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy. Cancers (Basel). 2020;13(1):48.
Article
CAS
Google Scholar
Jiang LR, Zhang N, Chen ST, He J, Liu YH, Han YQ, Shi XQ, Yang JJ, Mu DY, Fu GH, et al. PD-1-Positive tumor-associated macrophages define poor clinical outcomes in patients with muscle invasive bladder cancer through potential CD68/PD-1 complex interactions. Front Oncol. 2021;11: 679928.
Article
PubMed
PubMed Central
Google Scholar
Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30(1):27–42.
Article
CAS
PubMed
Google Scholar
Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–51.
Article
CAS
PubMed
Google Scholar
Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhou Q, Wang Z, Zeng H, Zhang H, Liu Z, Huang Q, Wang J, Chang Y, Bai Q, Liu L, et al. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin(+) cell abundance. Oncoimmunology. 2020;9(1):1747333.
Article
PubMed
PubMed Central
Google Scholar
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The immune landscape of cancer. Immunity. 2018;48(4):812-830.e814.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mo Q, Nikolos F, Chen F, Tramel Z, Lee YC, Hayashi K, Xiao J, Shen J, Chan KS. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J Natl Cancer Inst. 2018;110(5):448–59.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sionov RV, Fainsod-Levi T, Zelter T, Polyansky L, Pham CT, Granot Z. Neutrophil Cathepsin G and tumor cell RAGE facilitate neutrophil anti-tumor cytotoxicity. Oncoimmunology. 2019;8(9): e1624129.
Article
PubMed
PubMed Central
Google Scholar
Morimoto-Kamata R, Yui S. Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells. Cancer Sci. 2017;108(8):1574–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Huang GZ, Wu QQ, Zheng ZN, Shao TR, Li F, Lu XY, Ye HY, Chen GX, Song YX, Zeng WS, et al. Bioinformatics Analyses Indicate That Cathepsin G (CTSG) is a Potential Immune-Related Biomarker in Oral Squamous Cell Carcinoma (OSCC). Onco Targets Ther. 2021;14:1275–89.
Article
PubMed
PubMed Central
Google Scholar
Chen X, Zhou Y, Li Z, Wang Z. Mining database for the expression and clinical significance of NF-kappaB family in hepatocellular carcinoma. J Oncol. 2020;2020:2572048.
PubMed
PubMed Central
Google Scholar
Grazioli P, Orlando A, Giordano N, Noce C, Peruzzi G, Scafetta G, Screpanti I, Campese AF. NF-kappaB1 regulates immune environment and outcome of notch-dependent t-cell acute lymphoblastic leukemia. Front Immunol. 2020;11:541.
Article
CAS
PubMed
PubMed Central
Google Scholar
Qadir J, Riaz SK, Sahar NE, Aman D, Khan MJ, Malik MFA. Transcriptional elucidation of tumor necrosis factor-alpha-mediated nuclear factor-kappaB1 activation in breast cancer cohort of Pakistan. J Cancer Res Ther. 2020;16(6):1443–8.
CAS
PubMed
Google Scholar
Hillmer EJ, Zhang H, Li HS, Watowich SS. STAT3 signaling in immunity. Cytokine Growth Factor Rev. 2016;31:1–15.
Article
PubMed
PubMed Central
Google Scholar
Lodyga M, Hinz B. TGF-beta1 - A truly transforming growth factor in fibrosis and immunity. Semin Cell Dev Biol. 2020;101:123–39.
Article
CAS
PubMed
Google Scholar
Gu Y, Li J, Guo D, Chen B, Liu P, Xiao Y, Yang K, Liu Z, Liu Q. Identification of 13 Key genes correlated with progression and prognosis in hepatocellular carcinoma by weighted gene co-expression network analysis. Front Genet. 2020;11:153.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ling A, Lofgren-Burstrom A, Larsson P, Li X, Wikberg ML, Oberg A, Stenling R, Edin S, Palmqvist R. TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer. Oncoimmunology. 2017;6(11): e1356143.
Article
PubMed
PubMed Central
Google Scholar
Lazaridou MF, Gonschorek E, Massa C, Friedrich M, Handke D, Mueller A, Jasinski-Bergner S, Dummer R, Koelblinger P, Seliger B. Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients. Oncoimmunology. 2020;9(1):1774323.
Article
PubMed
PubMed Central
Google Scholar
Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, Cheng L, Montironi R. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers (Basel). 2021;13(1):131.
Article
CAS
PubMed Central
Google Scholar
Tu MM, Ng TL, De Jong FC, Zuiverloon TCM, Fazzari FGT, Theodorescu D. Molecular biomarkers of response to PD-1/PD-L1 immune checkpoint blockade in advanced bladder cancer (vol 5, pg 131, 2019). Bladder Cancer. 2020;6(4):559–559.
Article
Google Scholar
Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F. Recent Advances in Targeting CD8 T-Cell immunity for more effective cancer immunotherapy. Front Immunol. 2018;9:14.
Article
PubMed
PubMed Central
CAS
Google Scholar
MacLeod MK, Clambey ET, Kappler JW, Marrack P. CD4 memory T cells: what are they and what can they do? Semin Immunol. 2009;21(2):53–61.
Article
CAS
PubMed
PubMed Central
Google Scholar
Imai N, Tawara I, Yamane M, Muraoka D, Shiku H, Ikeda H. CD4(+) T cells support polyfunctionality of cytotoxic CD8(+) T cells with memory potential in immunological control of tumor. Cancer Sci. 2020;111(6):1958–68.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen D, Xie J, Fiskesund R, Dong W, Liang X, Lv J, Jin X, Liu J, Mo S, Zhang T, et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat Commun. 2018;9(1):873.
Article
PubMed
PubMed Central
CAS
Google Scholar